Kieran Adam

Kieran Adam

Auto-generated profile, based on publicly available information

Kieran Adam

University of Pittsburgh School of Medicine 1 Department of Immunology Pittsburgh, PA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2022 in Life Science Alliance
Verified
Journal Article
Open access
PDF file
YGYevgeniya Gartshteyn
Yevgeniya Gartshteyn
AAAnca D Askanase
Anca D Askanase
RSRuijiang Song
Ruijiang Song
SBShoiab Bukhari
Shoiab Bukhari
MDMatthew Dragovich
Matthew Dragovich
AMAdam Mor
Adam Mor
Signaling lymphocyte activation molecule family member 6 (SLAMF6) is a T cell co-receptor. Previously, we showed that SLAMF6 clustering was required for T cell activation. To better understand the relationship between SLAMF6 location and function and to evaluate the role of SLAMF6 as a therapeutic target, we investigated how its compartmentalization on the cell surface affects T cell functions. We used biochemical and co-culture assays to show that T cell activity is enhanced when SLAMF6 colocalizes with the CD3 complex. Mechanistically, co-immunoprecipitation analysis revealed the SLAMF6-interacting proteins to be those essential for signaling downstream of T cell receptor, suggesting the two receptors share downstream signaling pathways. Bispecific anti-CD3/SLAMF6 antibodies, designed to promote SLAMF6 clustering with CD3, enhanced T cell activation. Meanwhile, anti-CD45/SLAMF6 antibodies inhibited SLAMF6 clustering with T cell receptor, likely because of the steric hindrance, but nevertheless enhanced T cell activation. We conclude that SLAMF6 bispecific antibodies have a role in modulating T cell responses, and future work will evaluate the therapeutic potential in tumor models.

22 May 2024 in The Journal of Immunology
Verified
Journal Article
Closed access
KAKieran Adam
Kieran Adam
ZLZhanna Lipatova
Zhanna Lipatova
MRMaria Abdul Ghafoor Raja
Maria Abdul Ghafoor Raja
AMArjun K Mishra
Arjun K Mishra
RMRoy A Mariuzza
Roy A Mariuzza
DVDario A A Vignali
Dario A A Vignali
Lymphocyte activation gene 3 (LAG3) is an inhibitory receptor that plays a critical role in controlling T cell tolerance and autoimmunity and is a major immunotherapeutic target. LAG3 is expressed on the cell surface as a homodimer but the functional relevance of this is unknown. In this study, we show that the association between the TCR/CD3 complex and a murine LAG3 mutant that cannot dimerize is perturbed in CD8+ T cells. We also show that LAG3 dimerization is required for optimal inhibitory function in a B16-gp100 tumor model. Finally, we demonstrate that a therapeutic LAG3 Ab, C9B7W, which does not block LAG3 interaction with its cognate ligand MHC class II, disrupts LAG3 dimerization and its association with the TCR/CD3 complex. These studies highlight the functional importance of LAG3 dimerization and offer additional approaches to therapeutically target LAG3.

3 June 2021 in Communications Biology
Verified
Journal Article
Open access
PDF file
MSMarianne Strazza
Marianne Strazza
IAInbar Azoulay-Alfaguter
Inbar Azoulay-Alfaguter
MPMichael Peled
Michael Peled
KAKieran Adam
Kieran Adam
AMAdam Mor
Adam Mor
The inhibitory receptor PD-1 is expressed on T cells to inhibit select functions when ligated. The complete signaling mechanism downstream of PD-1 has yet to be uncovered. Here, we discovered phosphoprotein associated with glycosphingolipid-enriched microdomains 1 (PAG) is phosphorylated following PD-1 ligation and associate this with inhibitory T cell function. Clinical cohort analysis correlates low PAG expression with increased survival from numerous tumor types. PAG knockdown in T cells prevents PD-1-mediated inhibition of cytokine secretion, cell adhesion, CD69 expression, and ERK204/187 phosphorylation, and enhances phosphorylation of SRC527 following PD-1 ligation. PAG overexpression rescues these effects. In vivo, PAG contributes greatly to the growth of two murine tumors, MC38 and B16, and limits T cell presence within the tumor. Moreover, PAG deletion sensitizes tumors to PD-1 blockade. Here PAG is established as a critical mediator of PD-1 signaling and as a potential target to enhance T cell activation in tumors.

1 January 2001 in Experimental and Clinical Immunogenetics
Verified
Journal Article
Closed access
AFA. Fleva
A. Fleva
MDM. Daniilidis
M. Daniilidis
JSJ. Sidiropoulos
J. Sidiropoulos
KAK. Adam
K. Adam
ATA. Tourkantonis
A. Tourkantonis
LHL. Hadzipetrou
L. Hadzipetrou
Objective: The aim of this study was to investigate the relationship between HLA molecules and the positive or negative response of atopic patients to specific immunotherapy (SIT). Methods: We studied 42 atopic multisensitive patients undergoing grass pollen immunotherapy, 42 parents of patients (30 mothers and 12 fathers) and 173 control individuals. HLA class I and class II antigens were typed by a microlymphocytotoxicity test. The typing of DRB1* alleles for atopic patients and their parents was based on the reverse hybridization principle, while for the control group, DNA-RFLP and PCR-SSP methods were used. Results: The frequency of B14 and DRB1*1101-4 antigens/alleles, as well as the A2B5DR11 haplotype, showed a statistically significant difference in those patients who responded to immunotherapy. On the other hand, HLA-A28, B8 and DRB1*0301 antigens/alleles, as well as the frequency of the A1B8 and A1B8DR3 haplotypes, were found to be significantly higher in patients who responded poorly to SIT. Discussion: Our findings support the hypothesis that treatment responsiveness may show an association to HLA molecules, which could thus play a role in the immunological selection and monitoring of atopic patient candidacy for SIT.

31 March 2026 in Journal of Experimental Medicine
Verified
Journal Article
Closed access
KAKieran R. Adam
Kieran R. Adam
ASAamir Suhail
Aamir Suhail
VKVijay K. Kuchroo
Vijay K. Kuchroo
DVDario A.A. Vignali
Dario A.A. Vignali
Inhibitory receptors (IRs) such as CTLA-4, PD-1, LAG3, TIM-3, and TIGIT are critical regulators of immune homeostasis, functioning to restrain excessive immune activation and prevent autoimmunity. While the blockade of IRs has transformed cancer immunotherapy by reinvigorating antitumor T cell responses, emerging strategies aim to harness the immunosuppressive potential of these receptors for treating autoimmune and inflammatory diseases. Agonistic antibodies that activate IR signaling have demonstrated promising results in preclinical models by promoting immune tolerance and suppressing pathological effector T cell functions. This review highlights recent progress in the development of agonistic IR-targeted therapies, examining their mechanisms of action, therapeutic efficacy, and the translational challenges that must be addressed to bring these innovative approaches into clinical practice for the management of autoimmunity and inflammatory disorders.